TORONTO, March25th, 2026 - MediPharm Labs Corp. (TSX: LABS)(OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" orthe "Company") a pharmaceutical company specialized inprecision-based cannabinoids, is pleased to announce it will release its fullyear and fourth quarter financial results for the three and twelve monthsended December 31st, 2025, before markets open on Monday,March 30th, 2026.
MediPharmLabs executive management team will also host a conference call and webcast onMonday March 30th, 2026, at 10:00 a.m. (Eastern time) to discuss theCompany’s financial results.
Conference Call Dial in Details:
North America Toll-Free: (888)330-2454
International Toll: +1 (240)789-2714
Conference ID: 4921762
Participants are asked to dial inapproximately 15 minutes before the start of the call.
Webcast:
A webcastwill be available by visiting the following link here - https://events.q4inc.com/attendee/532172494
For thosewho are unable to participate on the live conference call or webcast, a replaywill be available at https://www.medipharmlabs.com/investors approximately one day aftercompletion of the call.
AboutMediPharm Labs
Founded in2015, MediPharm Labs specializes in the development and manufacture ofpurified, pharmaceutical-quality cannabis concentrates, active pharmaceuticalingredients (API) and advanced derivative products utilizing a GoodManufacturing Practices certified facility with ISO standard-built clean rooms.MediPharm Labs has invested in an expert, research driven team,state-of-the-art technology, downstream purification methodologies andpurpose-built facilities for delivery of pure, trusted and precision-dosedcannabis products for its customers. MediPharm Labs develops, formulates,processes, packages and distributes cannabis and advanced cannabinoid-basedproducts to domestic and international medical markets.
In 2021,MediPharm Labs received a Pharmaceutical Drug Establishment License from HealthCanada, becoming the only company in North America to hold acommercial-scale domestic Good Manufacturing Practices License for theextraction of multiple natural cannabinoids. This GMP license was the firststep in the Company's current foreign drug manufacturing site registration withthe US FDA.
In 2023,MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm's reach tomedical patients in Canada via Canna Farms medical ecommerceplatform, and in Australia and Germany through BeaconMedical PTY and Beacon Medical GMBH. This acquisition also included HarvestMedical Clinics in Canada which provides medical cannabis patientswith Physician consultations for medical cannabis education and prescriptions.
The Companycarries out its operations in compliancewith all applicable laws in the countries in which it operates.
Website: www.medipharmlabs.com
Cautionary Note Regarding Forward-Looking Information
This news release contains"forward-looking information" and "forward-lookingstatements" (collectively, "forward-looking statements") withinthe meaning of the applicable Canadian securities legislation. All statements,other than statements of historical fact, are forward-looking statements andare based on expectations, estimates and projections as at the date of thisnews release. Any statement that involves discussions with respect topredictions, expectations, beliefs, plans, projections, objectives, assumptions,future events or performance (often but not always using phrases such as"expects", or "does not expect", "is expected","anticipates" or "does not anticipate", "plans","budget", "scheduled", "forecasts","estimates", "believes" or "intends" orvariations of such words and phrases or stating that certain actions, events orresults "may" or "could", "would","might" or "will" be taken to occur or be achieved) are notstatements of historical fact and may be forward-looking statements. In this newsrelease, forward-looking statements relate to, among other things, statementsregarding the release of MediPharm's financial results and the future ofMediPharm's foreign drug manufacturing site registration. Forward-lookingstatements are necessarily based upon a number of estimates and assumptionsthat, while considered reasonable, are subject to known and unknown risks,uncertainties, and other factors which may cause the actual results and futureevents to differ materially from those expressed or implied by suchforward-looking statements. Such factors include, but are not limited to:general business, economic, competitive, political and social uncertainties;the inability of MediPharm to obtain adequate financing; the delay or failureto receive regulatory approvals; and other factors discussed in MediPharm'sfilings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements willprove to be accurate, as actual results and future events could differmaterially from those anticipated in such statements. Accordingly, readersshould not place undue reliance on the forward-looking statements andinformation contained in this news release. Except as required by law,MediPharm assumes no obligation to update the forward-looking statements ofbeliefs, opinions, projections, or other factors, should they change.
For further information, pleasecontact: MediPharm Labs Investor Relations,
Telephone: 1 416.913.7425,Email: investors@medipharmlabs.com